November 12, 2019
After yesterday’s Veteran’s Day holiday and low volume and percentage (%) movements to the downside
Earnings today: Biostage (BSTG), Sage therapeutics (SAGE), Intrexon (XON), Editas Medicine (EDIT) and BioLife Solutions (BLFS)
How does the old Ben Graham quote go? "In the short run, the market is a voting machine but in the long run it is a weighing machine"?
November 3, 2019
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5;
AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6;
Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7
…. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
November 12, 2019
… As the overbought barrel sprung a leak
Following the market closing lower amid lingering U.S.- China trade worries while protests in Hong Kong escalated
In “our’ universe of cell and gene therapy, we are betting on the hope for a cure or a treatment but, we are dependent on the management team to represent our hopes and aspirations.
November 3, 2019
Fate Therapeutics (FATE), Vericel (VCEL), Regenxbio (RGNX) and Ultragenyx (RARE) on 11/5; AxoGen (AXGN), Athersys (ATHX), Ionis Pharmaceuticals (IONS), Sangamo Therapeutics (SGMO), Voyager Therapeutics (VYGR), Bellicum Pharmaceuticals (BLCM) and Caladrius Biosciences (CLBS) on 11/6; Adverum Biotechnologies (ADVM), Audentes Therapeutics (BOLD) and Cellectis (CLLS) and Stemline Therapeutics (STML) on 11/7 …. and Biostage (BSTG) , BioLife Solutions (BLFS), and Applied Genetic Technologies (AGTC) on 10/12
September 11, 2019
We should all observe (along with the NYSE) a minute of silence to honor the 9/11 terror attack victims and their families as well as the survivors and first-responders
August 5, 2019
A scorecard of earnings of 45 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
